Studio in aperto per valutare la sicurezza e l'efficacia di CABA-201 in soggetti con miopatia infiammatoria idiopatica attiva
Uno studio di fase 1/2, in aperto, per valutare la sicurezza e l'efficacia delle cellule T autologhe del recettore chimerico specifico per l'antigene CD19 (CABA-201) in soggetti con miopatia infiammatoria idiopatica attiva
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Cabaletta Bio
- Numero di telefono: 4444 267-759-3100
- Email: clinicaltrials@cabalettabio.com
Luoghi di studio
-
-
-
Göttingen, Germania, 37075
- Non ancora reclutamento
- Universitätsmedizin Göttingen - Accepting Adult Patients
-
Contatto:
- Dr. Jana Zschüntzsch
- Email: j.zschuentzsch@med.uni-goettingen.de
-
Investigatore principale:
- Dr. Jana Zschüntzsch
-
-
-
-
-
Roma, Italia, 00165
- Reclutamento
- Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
-
Contatto:
- Dr. Marco Becilli
- Numero di telefono: +39 0668592739
- Email: marco.becilli@opbg.net
-
Investigatore principale:
- Professor Franco Locatelli
-
-
-
-
-
London, Regno Unito, WC1N 3BG
- Reclutamento
- University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
-
Contatto:
- Dr. Pedro Machado, FRCP, PhD
- Numero di telefono: 020 3456 7890
- Email: uclh.car-ttrials@nhs.net
-
Investigatore principale:
- Dr. Pedro Machado, FRCP, PhD
-
London, Regno Unito, SE5 9RS
- Reclutamento
- Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
-
Contatto:
- Rheumatology Research Team
- Numero di telefono: 0628 0207 848 0214
- Email: Kch-tr.CRDresearch@nhs.net
-
Investigatore principale:
- Patrick Gordon, PhD, FRCP, MBBS
-
London, Regno Unito, WC1N 3JH
- Reclutamento
- Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
-
Contatto:
- Professor Despina Eleftheriou
- Numero di telefono: 020 7405 9200
- Email: Despina.Eleftheriou@gosh.nhs.uk
-
Investigatore principale:
- Professor Despina Eleftheriou
-
Manchester, Regno Unito, M13 9WL
- Reclutamento
- Manchester Royal Infirmary - Accepting Adult Patients
-
Contatto:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
- Numero di telefono: 01612765052
- Email: Eleni.Tholouli@mft.nhs.uk
-
Investigatore principale:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
-
Salford, Regno Unito, M6 8HD
- Reclutamento
- Salford Royal Hospital - Accepting Adult Patients
-
Contatto:
- Michelle Beswick
- Numero di telefono: 07759 136787
- Email: Rheumatology.Research@nca.nhs.uk
-
Investigatore principale:
- Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
-
-
-
-
California
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- University of California Irvine - Accepting Adult Patients
-
Investigatore principale:
- Tahseen Mozaffar, MD
-
Contatto:
- Alpha Clinic
- Numero di telefono: 949-824-3990
- Email: alphaclinic@uci.edu
-
San Francisco, California, Stati Uniti, 94158
- Reclutamento
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
-
Contatto:
- Zilan Zheng
- Numero di telefono: 415-353-1301
- Email: Zilan.Zheng@ucsf.edu
-
Investigatore principale:
- Susan Kim, MD, MMSc
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80046
- Reclutamento
- Children's Hospital Colorado - Accepting Juvenile Patients
-
Investigatore principale:
- Dr. Kentaro Yomogida, MD
-
Contatto:
- Callie Strini - Primary Clinical Research Coordinator
- Numero di telefono: 720-777-9845
- Email: callie.strini@childrenscolorado.org
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32224
- Reclutamento
- Mayo Clinic Florida - Accepting Adult Patients
-
Contatto:
- Gabrielle Pariseau
- Numero di telefono: 904-953-5549
- Email: pariseau.gabrielle@mayo.edu
-
St. Petersburg, Florida, Stati Uniti, 33701
- Reclutamento
- Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
-
Investigatore principale:
- Natalie Booth, DO
-
Contatto:
- Laura Escobar
- Numero di telefono: 727-767-2946
- Email: llabarr2@jh.edu
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30032
- Reclutamento
- Emory University - Accepting Adult Patients
-
Contatto:
- John Varghese
- Email: john.varghese@emory.edu
-
Investigatore principale:
- Prateek Chandrashekar Gandiga, MD, FACP
-
Atlanta, Georgia, Stati Uniti, 30029
- Reclutamento
- Children's Healthcare of Atlanta - Accepting Juvenile Patients
-
Investigatore principale:
- Shanmuganathan Chandrakasan, MD
-
Contatto:
- Judson Russell
- Numero di telefono: 404-785-7263
- Email: Judson.russell@choa.org
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Northwestern Memorial Hospital - Accepting Adult Patients
-
Investigatore principale:
- Dr. George Georges, MD
-
Contatto:
- Kaitlin King
- Numero di telefono: 312-695-0990
- Email: autoimmunesct@nm.org
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients
-
Investigatore principale:
- Dr. Iazsmin Ventura, MD
-
Contatto:
- Dr. Iazsmin Ventura, MD - Adult patient contact
- Numero di telefono: 773-702-6619
- Email: iventura@uchicago.edu; Dequana.jones@bsd.uchicago.edu
-
Sub-investigatore:
- Dr. Cuoghi Edens, MD, FAAP
-
Contatto:
- Dr. Cuoghi Edens, MD, FAAP - Juvenile patient contact
- Email: cedens@bsd.uchicago.edu; Sydni.Hill@bsd.uchicago.edu
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
-
Contatto:
- Tyler Sorensen
- Numero di telefono: 312-277-6828
- Email: tsorensen@luriechildrens.org
-
Investigatore principale:
- Pooja N. Patel, DO
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- Reclutamento
- University of Kansas Medical Center - Accepting Adult Patients
-
Contatto:
- Samantha Colgan
- Numero di telefono: 913-945-9938
- Email: scolgan@kumc.edu
-
-
Maryland
-
Bethesda, Maryland, Stati Uniti, 20892
- Reclutamento
- National Institutes of Health - Accepting Adult and Juvenile Patients
-
Contatto:
- Julie Thompson
- Numero di telefono: 301-480-3191
- Email: Julie.thompson@nih.gov
-
Investigatore principale:
- Andrew Mammen, M.D., Ph.D.
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Reclutamento
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
-
Investigatore principale:
- Susan Prockop, MD
-
Contatto:
- Kyle McBrearty
- Numero di telefono: 617-355-2780
- Email: kyle.mcbrearty@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48105
- Reclutamento
- University of Michigan - Accepting Young Adult and Juvenile Patients
-
Contatto:
- Abigail Whalen
- Numero di telefono: 734-615-4466
- Email: abigaiwh@med.umich.edu
-
Investigatore principale:
- Dr. Jennifer Agrusa, MD
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55902
- Reclutamento
- Mayo Clinic - Accepting Adult Patients
-
Contatto:
- Bridget Neja
- Numero di telefono: 507-266-9150
- Email: neja.bridget@mayo.edu
-
-
New York
-
New York, New York, Stati Uniti, 10021
- Reclutamento
- Hospital for Special Surgery - Accepting Adult and Juvenile Patients
-
Contatto:
- Janvi Bhatia
- Numero di telefono: 212-774-2123
- Email: bhatiaj@hss.edu
-
Investigatore principale:
- David R. Fernandez, MD, PhD
-
New York, New York, Stati Uniti, 10021
- Reclutamento
- Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
-
Investigatore principale:
- Jae Park, MD
-
Contatto:
- Atifah Osrat
- Numero di telefono: 646-608-2091
- Email: osrata1@mskcc.org
-
The Bronx, New York, Stati Uniti, 10467
- Reclutamento
- Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
-
Contatto:
- Emily Gillies
- Numero di telefono: 718-696-2402
- Email: egillies@montefiore.org
-
Investigatore principale:
- Dr. Dawn Wahezi, MD, MS
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- Reclutamento
- University of North Carolina at Chapel Hill - Accepting Adult Patients
-
Investigatore principale:
- Saira Sheikh, MD
-
Contatto:
- Leah Luizza
- Email: leah.luizza@med.unc.edu
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients
-
Investigatore principale:
- Kaveh Ardalan, MD, MS
-
Contatto:
- Lynn Rodgers, MS
- Numero di telefono: 919-668-2953
- Email: Lynn.rodgers@duke.edu
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Reclutamento
- Oregon Health & Science University - Accepting Adult Patients
-
Contatto:
- Katie Lewis
- Numero di telefono: 503-908-9724
- Email: lewiskat@ohsu.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
-
Contatto:
- CARTintake@chop.edu
- Email: CARTintake@chop.edu
-
Investigatore principale:
- Dr. Caitlin Elgarten, MD, MSCE
-
Pittsburgh, Pennsylvania, Stati Uniti, 15261
- Reclutamento
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
-
Contatto:
- Carol Oriss
- Email: orissca@upmc.edu
-
Investigatore principale:
- Jeremy Tilstra, MD
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- Reclutamento
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
-
Contatto:
- Vibha Chauhan, PhD
- Numero di telefono: 412-692-7924
- Email: Vibha.chauhan@chp.edu
-
Investigatore principale:
- Kathryn Torok, MD
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Vanderbilt University Medical Center - Accepting Adult Patients
-
Contatto:
- Tofi Soneye
- Numero di telefono: 817-883-4730
- Email: tofi.soneye@vumc.org
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- Reclutamento
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients
-
Investigatore principale:
- Samuel John, MD
-
Contatto:
- Dr. Samuel John
- Email: dtpteam@childrens.com
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Houston Methodist Hospital - Accepting Adult Patients
-
Contatto:
- Amelia A. Nounes, MSN, RN, CCRP
- Numero di telefono: 346-356-3639
- Email: aanounes@houstonmethodist.org
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients
-
Investigatore principale:
- Huifang (Linda) Lu, MD
-
Contatto:
- Christina Amos Briggs, BSN, RN
- Numero di telefono: 713-563-5076
- Email: cbamos@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84113
- Reclutamento
- Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
-
Contatto:
- Morgan Badgley - Research Coordinator
- Numero di telefono: 801-662-4812
- Email: morgan.badgley@hsc.utah.edu
-
Investigatore principale:
- Aimee Ogden Hersh, MD
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Reclutamento
- Seattle Children's Research Institute - Accepting Juvenile Patients
-
Contatto:
- Dr. Susan Shenoi, MD, MS
- Numero di telefono: 206-987-2193
- Email: susan.shenoi@SeattleChildrens.org
-
Investigatore principale:
- Dr. Susan Shenoi, MD, MS
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Non ancora reclutamento
- Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
-
Investigatore principale:
- Sara Sabbagh, DO
-
Contatto:
- Erin Hammelev - Research Coordinator
- Numero di telefono: 414-337-7064
- Email: ehammele@mcw.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Adult Cohorts
Inclusion Criteria:
- Age ≥18 and ≤75
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Diagnosis of DM, ASyS, or IMNM
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
- Presence of muscle weakness
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Juvenile Cohort
Inclusion Criteria:
- Age ≥6 and ≤17 years at enrollment
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: CABA-201 Phase 1/2
DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM. ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS. IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Altri nomi:
|
|
Sperimentale: CABA-201 Phase 2b - Sub-study 1
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Altri nomi:
|
|
Sperimentale: CABA-201 Phase 2b - Sub-study 2
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 1/2: Incidence and severity of adverse events (AEs)
Lasso di tempo: Up to 28 days after CABA-201 infusion
|
Incidence and severity of AEs |
Up to 28 days after CABA-201 infusion
|
|
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Within 16 weeks
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 16 weeks
|
|
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Within 24 weeks
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 24 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of adverse events and laboratory abnormalities
Lasso di tempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Incidence and severity of AEs, including changes in laboratory values and vital signs |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacodynamics (PD)
Lasso di tempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of B cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacokinetics (PK)
Lasso di tempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of CABA-201-positive T cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Change in disease-related biomarkers of muscle inflammation
Lasso di tempo: Up to 156 weeks (Phase 1/2)
|
Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum |
Up to 156 weeks (Phase 1/2)
|
|
Change in autoantibody-related biomarkers
Lasso di tempo: Up to 156 weeks (Phase 1/2)
|
Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum |
Up to 156 weeks (Phase 1/2)
|
|
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Week 16 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Week 16 (Sub-study 1)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 16 (Sub-study 1)
|
|
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Week 16 (Sub-study 1)
|
≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Lasso di tempo: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Lasso di tempo: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Week 24 (Sub-study 2)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 24 (Sub-study 2)
|
|
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Week 52 (Sub-study 2)
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 2)
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Cattedra di studio: Medical Director, Cabaletta Bio
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- Miosite
- Dermatomiosite
- Malattia autoimmune
- Terapia cellulare
- Dermatomiosite giovanile
- CABA-201
- Terapia CAR-T anti-CD19
- Miopatia infiammatoria idiopatica
- Sindrome da antisintetasi
- Miopatia necrotizzante immunomediata
- Polimiosite giovanile
- Miopatia infiammatoria idiopatica giovanile (JIIM)
- Miosite giovanile
Termini MeSH pertinenti aggiuntivi
- Malattie muscoloscheletriche
- Malattie del sistema nervoso
- Malattie muscolari
- Malattie neuromuscolari
- Malattie del tessuto connettivo
- Malattie del sistema immunitario
- Malattie della pelle
- Polimiosite
- Malattie della pelle e del tessuto connettivo
- Malattie autoimmuni
- Dermatomiosite
- Miosite
- Prodotti chimici organici
- Idrocarburi
- Senape di fosforamide
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Fosforamidi
- Composti organofosfori
- Ciclofosfamide
- fludarabina
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CAB-201-002
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .